Description
Crizotinib
EACH LUCICRIZ CAPSULE CONTAINS
Crizotinib … 250mg
INDICATION
LuciCriz is a kinase inhibitor indicated for the treatment of patients with metastatic nonsmall cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1 – positive as detected by an FDA-approved test.
DOSAGE AND USE
The recommended dosage is 250 mg orally twice daily. Capsules should be swallowed whole & not chewed or crushed.
STORAGE
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Keep medicine out of the reach of Children.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING AND PRECAUTION
To be sold by retail on prescription of a Registered oncologist only, and as directed by the physician.
Reviews
There are no reviews yet.